Marta Kruszyna-Mochalska

Mrs. Marta Kruszyna-Mochalska

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Radiology and Oncology
Verified
Journal Article
Open access
PDF file
IPIgor Piotrowski
Igor Piotrowski
KKKatarzyna Kulcenty
Katarzyna Kulcenty
WSWiktoria Suchorska
Wiktoria Suchorska
ASAgnieszka Skrobała
Agnieszka Skrobała
MSMałgorzata Skórska
Małgorzata Skórska
Julian MalickiJulian Malicki
Julian Malicki
Background: Although the effects of high dose radiation on human cells and tissues are relatively well defined, there is no consensus regarding the effects of low and very low radiation doses on the organism. Ionizing radiation has been shown to induce gene mutations and chromosome aberrations which are known to be involved in the process of carcinogenesis. The induction of secondary cancers is a challenging long-term side effect in oncologic patients treated with radiation. Medical sources of radiation like intensity modulated radiotherapy used in cancer treatment and computed tomography used in diagnostics, deliver very low doses of radiation to large volumes of healthy tissue, which might contribute to increased cancer rates in long surviving patients and in the general population. Research shows that because of the phenomena characteristic for low dose radiation the risk of cancer induction from exposure of healthy tissues to low dose radiation can be greater than the risk calculated from linear no-threshold model. Epidemiological data collected from radiation workers and atomic bomb survivors confirms that exposure to low dose radiation can contribute to increased cancer risk and also that the risk might correlate with the age at exposure. Conclusions: Understanding the molecular mechanisms of response to low dose radiation is crucial for the proper evaluation of risks and benefits that stem from these exposures and should be considered in the radiotherapy treatment planning and in determining the allowed occupational exposures.

30 June 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KLKatarzyna Monika Lamperska
Katarzyna Monika Lamperska
TKTomasz Kolenda
Tomasz Kolenda
ATAnna Teresiak
Anna Teresiak
AKAnna Kowalik
Anna Kowalik
MKMarta Kruszyna-Mochalska
Marta Kruszyna-Mochalska
Piotr KozlowskiPiotr Kozlowski
Piotr Kozlowski
The implication of the let-7 family in cancer development is multifaceted. The family acts as tumor suppressor miRNA although overexpression of let-7 has also been described in many types of cancer, including head and neck squamous cell carcinoma (HNSCC). The aim of this study includes whether different expression levels of let-7d has an influence on chemo- and radiosensitivity. FaDu cell line models with a gradually increased level of let-7d (models from A to E) were generated with the lentiviral system. Expression levels of pluripotency, chemo-radioresistance/apoptosis, and targets of mRNAs were analyzed by real-time reverse transcription-PCR (qRT-PCR). Radiosensitivity was analyzed using a clonogenic assay after irradiation. Response to cisplatin, 5-FU, doxorubicin, and paclitaxel was done with MTT assay. Statistically significant decrease of K-RAS (p = 0.0369) and CASPASE3 (p = 0.0342) were observed with the growing expression level of let-7d. Cisplatin, 5-FU and doxorubicin caused similar decreased of cell survival with the increase of let-7d level (p = 0.004, post-trend p = 0.046; p = 0.004, post trend p = 0.0005 and p<0.0001, post trend p = 0.0001, respectively). All models were resistant to paclitaxel, irrespective of let-7d expression levels. Only two of the generated models (A and C) were radiosensitive (p = 0.0002). Conclusion: the above results indicated that the level of let-7d expression is an important factor for cell response to irradiation and chemotherapeutics.

1 September 2017 in Reports of Practical Oncology and Radiotherapy
Verified
Journal Article
Closed access
MTMaria Glòria Torras
Maria Glòria Torras
MFMagdalena Fundowicz
Magdalena Fundowicz
LALuisa Aliste
Luisa Aliste
EAEsther Asensio
Esther Asensio
ABAnna Maria Boladeras
Anna Maria Boladeras
Julian MalickiJulian Malicki
Julian Malicki
As radiotherapy practice and processes become more complex, the need to assure quality control becomes ever greater. At present, no international consensus exists with regards to the optimal quality control indicators for radiotherapy; moreover, few clinical audits have been conducted in the field of radiotherapy. The present article describes the aims and current status of the international IROCA "Improving Radiation Oncology Through Clinical Audits" project. The project has several important aims, including the selection of key quality indicators, the design and implementation of an international audit, and the harmonization of key aspects of radiotherapy processes among participating institutions. The primary aim is to improve the processes that directly impact clinical outcomes for patients. The experience gained from this initiative may serve as the basis for an internationally accepted clinical audit model for radiotherapy.

1 August 2017 in Cancer/Radiothérapie
Verified
Journal Article
Closed access
MKMarta Kruszyna-Mochalska
Marta Kruszyna-Mochalska
SAS. Adamczyk
S. Adamczyk
ASAgnieszka Skrobała
Agnieszka Skrobała
MSM. Skórska
M. Skórska
WSWiktoria Suchorska
Wiktoria Suchorska
Julian MalickiJulian Malicki
Julian Malicki

1 August 2017 in Cancer/Radiothérapie
Verified
Journal Article
Closed access
ASAgnieszka Skrobała
Agnieszka Skrobała
SAS. Adamczyk
S. Adamczyk
MKMarta Kruszyna-Mochalska
Marta Kruszyna-Mochalska
MSM. Skórska
M. Skórska
AKA. Konefał
A. Konefał
Julian MalickiJulian Malicki
Julian Malicki

1 February 2022 in Journal of Applied Clinical Medical Physics
Verified
Journal Article
Open access
PDF file
MKMarta Kruszyna-Mochalska
Marta Kruszyna-Mochalska
ASAgnieszka Skrobala
Agnieszka Skrobala
PRPiotr Romanski
Piotr Romanski
ARAdam Ryczkowski
Adam Ryczkowski
WSWiktoria Suchorska
Wiktoria Suchorska
JMJulian Malicki
Julian Malicki
Our understanding of low dose, out‐of‐field radiation and their radiobiological effects are limited, in part due to the rapid technological advances in external beam radiotherapy, especially for non‐coplanar and dynamic techniques. Reliable comparisons of out‐of‐field doses produced by advanced radiotherapy techniques are difficult due to the limitations of commercially available phantoms. There is a clear need for a functional phantom to accurately measure the dosimetric and radiobiological characteristics of out‐of‐field doses, which would in turn allow clinicians and medical physicists to optimize treatment parameters. We designed, manufactured, and tested the performance of a quasi‐humanoid (Q‐H) adult phantom. To test the physics parameters, we used computed tomography (CT) scans of assembled Q‐H phantom. Static open field and dynamic techniques were measured both in‐ and out‐of‐field with ionization chambers and radiochromic films for two configurations (full solid and with water‐filled containers). In the areas simulating soft tissues, lung, and bones, median Hounsfield units and densities were, respectively: 129.8, ‐738.7, 920.8 HU and 1.110, 0.215, 1.669 g/cm3. Comparison of the measured to treatment planning systems (TPS) in‐field dose values for the sample volumetric arc therapy (VMAT) (6 MV flattening filter‐free (FFF)) plan, 96.4% of analyzed points passed the gamma evaluation criteria (L2%/2 mm, threshold (TH) 10%) and less than 1.50% for point dose verification. In the two phantom configurations: full poly(methyl) methacrylate (PMMA) and with water container, the off‐axis median doses for open field, relative to the central axis of the beam (CAX) were similar, respectively: 0.900% versus 0.907% (15 cm distance to CAX); 0.096% versus 0.120% (35 cm); 0.018% versus 0.018% (52 cm); 0.009% versus 0.008% (74 cm). For VMAT 6 MV FFF, doses relative the CAX were, respectively: 0.667% (15 cm), 0.062% (35 cm), 0.019% (52 cm), 0.016% (74 cm). The Q‐H phantom meets the International Commission on Radiation Units and Measurements (ICRU) and American Association of Physicists in Medicine (AAPM) recommended phantom criteria, providing medical physicists with a reliable, comprehensive system to perform dose calculation and measurements and to assess the impact on radiobiological response and on the risk of secondary tumor induction.